Abstract
Pharmacological memory reconsolidation blockade provides a potential mechanism for ameliorating the maladaptive reward memories underlying relapse in addiction. Two of the most promising classes of drug that interfere with reconsolidation and have translational potential for human use are N-methyl-D-aspartate receptor (NMDAR) and B-Adrenergic receptor (B-AR) antagonists. We used meta-analysis and meta-regression to assess the effects of these drugs on the reconsolidation of reward memory in preclinical models of addiction. Pharmacokinetic, mnemonic and methodological factors were assessed for their moderating impact on effect sizes. An analysis of 52 independent effect sizes (NMDAR=30, B-AR=22) found robust effects of both classes of drug on memory reconsolidation, but a far greater overall effect of NMDAR antagonism than B-AR antagonism. Significant moderating effects of drug dose, relapse process and primary reinforcer were found. The findings suggest that reward memory reconsolidation can be robustly targeted by NMDAR antagonists and to a lesser extent, by B-AR antagonists. Implications for future clinical work are discussed.
Original language | English |
---|---|
Pages (from-to) | 240-255 |
Number of pages | 16 |
Journal | Neuroscience and Biobehavioral Reviews |
Volume | 37 |
Issue number | 3 |
Early online date | 20 Dec 2012 |
DOIs | |
Publication status | Published - Mar 2013 |
Keywords
- Adrenergic Antagonists/pharmacology
- Animals
- Behavior, Addictive/drug therapy
- Humans
- Memory/drug effects
- Receptors, Adrenergic, beta/metabolism
- Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors
- Reward